Biomimetic Hybrid PROTAC Nanovesicles Block Multiple DNA Repair Pathways to Overcome Temozolomide Resistance Against Orthotopic Glioblastoma
Advanced Materials · 2025-07 · 37 (29)
DOI: 10.1002/adma.202504253 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 09.05.2025. Verfasst von Qing Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou, 511442, P.R. China. Hauptthemen laut MEDLINE: Glioblastoma, Temozolomide, Drug Resistance, Neoplasm, DNA Repair. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangdong Provincial Pearl River Talents Program, Key Technologies Research and Development Program.
Abstract (Originalsprache)
Glioblastoma (GBM) remains one of the deadliest forms of cancer due to its high rates of postoperative recurrence and resistance to treatment. Temozolomide (TMZ) is the standard chemotherapy for GBM. However, the therapeutic efficacy of TMZ is significantly compromised by the activation of various intracellular DNA repair mechanisms that facilitate TMZ resistance. Herein, the upregulation of bromodomain‐containing protein 4 (BRD4) expression is demonstrated to be a key contributor to TMZ resistance in GBM. To address this challenge, a biomimetic hybrid PROteolysis TArgeting Chimeras (PROTAC) liposome delivery system (M@TP) is developed. This system efficiently penetrates the blood‐brain barrier (BBB) and specifically targets GBM cells through homotypic recognition. Once within TMZ‐resistant GBM cells, the released PROTAC from M@TP can specifically degrade BRD4, effectively inhibiting multiple DNA repair pathways and restoring sensitivity to TMZ treatment. In vivo, studies showed that M@TP demonstrated significant efficacy in suppressing tumor growth in both TMZ‐resistant and postoperative GBM, with prolonged mouse survival times. These findings highlight the potential of M@TP as a promising strategy to overcome TMZ resistance and improve therapeutic outcomes in GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou, 511442, P.R. China.
- National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou, 510006, P.R. China.
- Key Laboratory of Biomedical Engineering of Guangdong Province, South China University of Technology, Guangzhou, 510006, P. R. China.
ORCID-Profile: Youyong Yuan
Förderung
- National Natural Science Foundation of China
- Guangdong Provincial Pearl River Talents Program
- Key Technologies Research and Development Program
Zitieren
APA
Xu, Q., Hu, X., Ullah, I., Lin, T., Liu, Y., Dong, H., Zong, Q., Yuan, Y., & Wang, J. (2025). Biomimetic Hybrid PROTAC Nanovesicles Block Multiple DNA Repair Pathways to Overcome Temozolomide Resistance Against Orthotopic Glioblastoma. Advanced Materials, 37(29). https://doi.org/10.1002/adma.202504253
Vancouver
Xu Q, Hu X, Ullah I, Lin T, Liu Y, Dong H, et al. Biomimetic Hybrid PROTAC Nanovesicles Block Multiple DNA Repair Pathways to Overcome Temozolomide Resistance Against Orthotopic Glioblastoma. Advanced Materials. 2025;37(29). doi:10.1002/adma.202504253
BibTeX
@article{Xu2025,
author = {Xu, Qing and Hu, Xiangyu and Ullah, Ihsan and Lin, Taian and Liu, Ye and Dong, He and Zong, Qingyu and Yuan, Youyong and Wang, Jun},
title = {Biomimetic Hybrid PROTAC Nanovesicles Block Multiple DNA Repair Pathways to Overcome Temozolomide Resistance Against Orthotopic Glioblastoma},
journal = {Advanced Materials},
year = {2025},
volume = {37},
number = {29},
doi = {10.1002/adma.202504253}
}
EUVIMED